AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 13 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Dendritic cells (DCs) engineered to carry B-cell, lymphoma-specific antigens can help patients fight off malignancy, researchers in the United States say.
"Tumor-specific clonal immunoglobulin expressed by B-cell lymphomas (idiotype [Id]) can serve as a target for active immunotherapy," according to Dr. John M. Timmerman and colleagues at the Stanford University School of Medicine in Stanford, California.
Therapeutic vaccination with idiotype-pulsed DCs can slow or reverse tumor progression, Timmerman and coauthors found.
After achieving promising results in a preliminary study with 4 B-cell lymphoma patients, the researchers inoculated 35 volunteers with idiotype-pulsed DCs. Ten patients were treated before receiving other therapy, while another 25 were vaccinated after their first chemotherapy regimen, according to the report.
Almost all of the therapy-naive study participants (8 of 10) showed antilymphoma immune responses, study data showed, and 4 of these patients remained progression free for as long as 6 years. Tumor regression was seen in almost a fourth (22%) of the inoculated patients with residual disease and 70% of the chemotherapy-treated patients did not suffer from disease progression for a median of more than three years after vaccination.
The immunogenic carrier protein keyhole limpet hemocyanin (Id-KLH) was needed for high ...
Source: HighBeam Research, Idiotype-pulsed dendritic cell vaccination effective.(Brief Article)